Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging ...

Cencora (NYSE:COR) has made headlines with its announcement on March 10, 2025, detailing plans for strategic acquisitions and investments in technology infrastructure, aiming to drive future growth.

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.

Cencora, Inc. COR is well-poised for growth ... 19.5% against the industry’s 3.5% growth so far this year. Our team of experts has just released the 5 stocks with the greatest probability ...

Baird raised the firm’s price target on Cencora (COR) to $307 from $305 and keeps an Outperform rating on the shares. The firm noted it was another beat and raise quarter. Published first on ...

Cencora, a global healthcare company, has expanded its Sure Supply Program to include 200 critical medications, including several oncology treatments, in response to ongoing drug shortages.

Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $280 from $270 and keeps a Buy rating on the shares. The company delivered strong results for Q1 and expects topline ...

The company is well-positioned to deliver long-term sustainable growth on the back of its diverse and inclusive teams. Cencora is an ideal partner for manufacturers looking to launch products.

Before we begin, I want to thank the 40-plus thousand global Cencora team members. It's because of their purpose-driven approach expertise and dedication to meeting the needs of customers and patients ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal first-quarter net income of $488.6 million. The Conshohocken, Pennsylvania-based company said ...